Primary contact

Karius is a life sciences company transforming infectious disease diagnostics with genomics. The company's platform uses a combination of machine-learning, proprietary signal processing algorithms, and next-generation sequencing to enable the broad and rapid detection of microbial cell-free DNA through a standard blood draw. Its Karius Test is dubbed the next-generation sequencing-based test that can identify more than 1,000 pathogens directly from blood, helping clinicians improve patient outcomes and helping industry accelerate drug development. Karius is also offering a laboratory service for pathogen biomarker detection to drive efficiency in biopharmaceutical clinical development.
Primary contact

Funding 💰

Total $55M
Select investors Data Collective, Lightspeed Venture Partners, Khosla Ventures, Innovation Endeavors, S28 Capital, Tencent, Pacific 8 Ventures
Last update: May 18, 2018